ATHEROSCLEROSIS TREATMENT DRUGS MARKET ANALYSIS

Atherosclerosis Treatment Drugs MarketSize and Trends

Atherosclerosis Treatment Drugs Market - Driver

Increasing number of pipeline studies and rising involvement of key players for developing the treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in August 2021.

Moreover, technological advancement in the atherosclerosis treatment procedures is expected to boost the atherosclerosis treatments drug market growth. For instance, in May 2017, Researchers at Ben-Gurion University (BGU) and the Sheba Medical Center developed Nano polymer therapy, a new therapy for the treatment of atherosclerosis. It prevents heart failure with a new biomedical polymer (E-selectin-targeting polymer) that reduces arterial plaque and inflammation in the cardiovascular system. E-selectin-targeting polymer helps to reduce existing plaque and impedes the further plaque formation. It also prevents arterial thrombosis, ischemia, myocardial infarction, and strokes.

Atherosclerosis Treatment Drugs Market- Taxonomy

By Drugs Type

• Cholesterol medications
• Beta Blockers
• Angiotensin-converting enzyme (ACE) Inhibitors
• Calcium Channel blocker
• Diuretics
• Antiplatelet
• Other Medications

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa